All In MedTech

Device Trial Radar · NCT06995898

The Vanguard Study: Testing a New Way to Screen for Cancer

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 24,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

24,000

Planned (sponsor's estimate)

Start

Jun 18, 2025

Primary completion

Jan 31, 2029

Study completion Jun 30, 2029

Sponsor

Sponsor type
NIH
First posted
May 30, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Conditions

  • Bladder Carcinoma
  • Breast Carcinoma
  • Colorectal Carcinoma
  • Esophageal Carcinoma
  • Gastric Carcinoma
  • Liver Carcinoma
  • Lung Carcinoma
  • Malignant Solid Neoplasm
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
  • Prostate Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood collection

  • Device UsageDevice

    Evaluation of MCD tests

  • Electronic Health Record ReviewOther

    Obtain health data

  • Multi-Cancer Early Detection TestProcedure

    Undergo Shield MCD test

  • Multi-Cancer Early Detection TestProcedure

    Undergo Avantect MCD test

  • Questionnaire AdministrationOther

    Study specific questionnaires

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of enrollment onto studyTime frame: At time of randomization
  2. Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receiptTime frame: Up to 3 years
  3. Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time pointTime frame: Up to 2 years

3 more outcomes with a free account

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente-Division of Research

    Pleasanton, California · Recruiting

  • Naval Medical Center -San Diego

    San Diego, California · Recruiting

  • Keefe Memorial Hospital

    Cheyenne Wells, Colorado · Recruiting

46 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.